FORM 8-K

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 


 

FORM 8-K

 


 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of

THE SECURITIES EXCHANGE ACT OF 1934

 

Date of Report (Date of Earliest Event Reported): May 3, 2004

 


 

OSCIENT PHARMACEUTICALS CORPORATION

(Exact name of registrant as specified in its charter)

 


 

Massachusetts   0-10824   04-2297484

(State or other jurisdiction

of incorporation)

 

(Commission

File Number)

 

(I.R.S. Employer

Identification Number)

 

100 Beaver Street

Waltham, Massachusetts 02453

(Address of principal executive offices, including zip code)

 

(781) 398-2300

(Registrant’s telephone number, including area code)

 



Item 7. FINANCIAL STATEMENTS AND EXHIBITS.

 

(c) Exhibits

 

99.1 Press Release issued by Oscient Pharmaceuticals Corporation on May 3, 2004.

 

Item 9. REGULATION FD DISCLOSURE

 

On May 3, 2004, Oscient Pharmaceuticals Corporation issued a press release announcing its intention to issue convertible notes. A copy of the press release is attached hereto as Exhibit 99.1.

 

2


SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

OSCIENT PHARMACEUTICALS CORPORATION

By:

 

/s/ Steven M. Rauscher


Name:

 

Steven M. Rauscher

Title:

 

President and Chief Executive Officer

 

Date: May 3, 2004

 

3


EXHIBIT INDEX

 

Exhibit Number

 

Description


99.1   Press Release issued by Oscient Pharmaceuticals Corporation on May 3, 2004.

 

4